FibroGen Inc FGEN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
-
FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update
-
FibroGen to Report Second Quarter 2024 Financial Results
-
FibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate Update
-
FibroGen To Begin Trials on Tumor Treatment After FDA OK
Trading Information
- Previous Close Price
- $0.40
- Day Range
- $0.36–0.40
- 52-Week Range
- $0.33–2.93
- Bid/Ask
- $0.37 / $0.39
- Market Cap
- $36.82 Mil
- Volume/Avg
- 915,203 / 1.8 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.21
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 486
- Website
- https://www.fibrogen.com
Comparables
Valuation
|
Metric
|
FGEN
|
EXEL
|
FULC
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 17.48 | — |
Price/Book Value | — | 3.59 | 0.87 |
Price/Sales | 0.21 | 4.08 | 2.94 |
Price/Cash Flow | — | 16.68 | — |
Price/Earnings
FGEN
EXEL
FULC
Financial Strength
|
Metric
|
FGEN
|
EXEL
|
FULC
|
|---|---|---|---|
Quick Ratio | 1.18 | 4.05 | 21.84 |
Current Ratio | 1.41 | 4.27 | 22.07 |
Interest Coverage | −8.04 | — | — |
Quick Ratio
FGEN
EXEL
FULC
Profitability
|
Metric
|
FGEN
|
EXEL
|
FULC
|
|---|---|---|---|
Return on Assets (Normalized) | −28.98% | 14.82% | −1.76% |
Return on Equity (Normalized) | — | 19.05% | −1.91% |
Return on Invested Capital (Normalized) | −1,208.96% | 14.99% | −1.83% |
Return on Assets
FGEN
EXEL
FULC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Nwgmgkfl | Spxxk | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Gymbgzjsj | Bqglf | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Grhpdpww | Nrhdsp | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Pwjfznyj | Gjhsmyr | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Tqgngrg | Pjfl | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Nqsnfhh | Dmt | $29.2 Bil | |||
| Moderna Inc
MRNA
| Mfpzlwsx | Gytz | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Nntyssf | Pbhvv | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Vvljvhdn | Zhccyf | $13.2 Bil | |||
| Incyte Corp
INCY
| Vptnsvzp | Zknfmgj | $13.0 Bil |
United States